Abstract No. 238 Premedication with NK-1 Antagonists and COX-2 Inhibitors Improves Same-Day Discharge Rates Following Chemoembolization for Hepatocellular Carcinoma and Neuroendocrine Liver Metastasis
Postembolization syndrome is common following transarterial chemoembolization (TACE) and bland embolization (TAE) for hepatocellular carcinoma (HCC) and neuroendocrine (NET) liver metastasis. NCCN antiemesis guidelines include neurokinin-1 antagonists (NK-1) in patients receiving emetogenic chemotherapy, however, these agents are not specified in current SIR guidelines. Surgical RCTs demonstrate decreased narcotic requirements when preoperative COX-2 inhibitors are given. The purpose of this study was to determine if adding an NK-1 antagonist and COX-2 inhibitor reduced post-procedural antiemetic and narcotic use or improved same-day discharge rates following TACE/TAE for HCC and NET liver metastasis.
vigna
0
0
Postembolization syndrome is common following transarterial chemoembolization (TACE) and bland embolization (TAE) for hepatocellular carcinoma (HCC) and neuroendocrine (NET) liver metastasis. NCCN antiemesis guidelines include neurokinin-1 antagonists (NK-1) in patients receiving emetogenic chemotherapy, however, these agents are not specified in current SIR guidelines. Surgical RCTs demonstrate decreased narcotic requirements when preoperative COX-2 inhibitors are given. The purpose of this study was to determine if adding an NK-1 antagonist and COX-2 inhibitor reduced post-procedural antiemetic and narcotic use or improved same-day discharge rates following TACE/TAE for HCC and NET liver metastasis.
